• Home
  • About Us
    • Member Directory
    • Contact Us
  • Blogs
    • Scientific Blogs
      • Technology
      • Environment
      • Health
    • Infinity Explorer
    • Traveler Book
    • Life Around
  • Publication
  • Scientific Advisory
  • Project
    • Future Projects
    • Ongoing Projects
    • Previous Projects
  • Services
    • Language Programs
    • Latest Software
    • Environmental Consultancy
    • Internship
    • Exercise
  • Career
    • Masters
    • PHDs
    • Postdoctorals
    • Travel Grants
    • Others

People Taking New Hunger-Blocking Drug Lose 24 Kilograms On Average

People Taking New Hunger-Blocking Drug Lose 24 Kilograms On Average

Share:

Twitter
Tweet
LinkedIn
Share
Facebook
fb-share-icon
WeChat
Follow by Email
Hardin Bitsky

Hardin Bitsky

Mr. Hardin, a future doctor of pharmacy, provides services as a content writer for scientific and technical niches.

Another week, another obesity drug tested – but a new one by the US pharmaceutical giant Lilly may prove to be promising, with people who had weekly injections of the drug losing 22.5 percent of their body weight on average.

Obesity is at global epidemic levels and spans many different ages and socioeconomic groups. There are many different weight loss programs and drugs available on the market, and new technologies and drugs are constantly being created and tested to help those who want to lose weight.

The human body is a very complex system and when the body needs energy (calories) it releases the hormone ghrelin, which in turn makes us feel hungry. After we have consumed a delicious meal, the body then produces less ghrelin and releases hormones like GLP-1 (glucagon-like peptide-1), PYY (peptide YY), and leptins. These hormones help us feel satiated.

When trying to lose weight, the satiety hormones actually decrease and the hunger hormones increase, making it difficult as it leads to the constant gnawing of hunger.

The new drug from Lilly is called tirzepatide, combining two synthetic hormone mimics; GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). In preclinical models, GIP seems to increase energy expenditure and decrease food intake. Combining GIP with GLP-1 receptor agonism could result in greater weight loss.

The company presented its study results on April 28, 2022. This study was the first phase 3 clinical trial to evaluate the efficacy and the safety of the drug in adults who do not have diabetes. The trial involved more than 2,500 people in nine countries. The participant’s average weight was 105 kilograms (230 pounds) and they were asked to give themselves weekly injections of the drug at low (5 mg), medium (10 mg), and high (15 mg) doses or a placebo for 72 weeks. This trial was a double-blinded, randomized, multi-center, parallel, placebo-controlled trial.

The most effective dosage of the drug was the highest, and on average this dosage helped reduce the body weight of the participants by 22.5 percent.

“Tirzepatide is the first investigational medicine to deliver more than 20 percent weight loss on average in a phase 3 study, reinforcing our confidence in its potential to help people living with obesity,” said Jeff Emmick, MD, PhD, vice president, product development, Lilly, in a statement.

This drug can trigger many side effects like vomiting, diarrhea, nausea, and constipation, which get worse the higher the dose. However, one advantage of obesity drugs is that they can be stopped at any time, unlike some surgical options like bariatric surgery which change how you eat for the rest of your life.

The company does need to conduct more monitoring to see if this drug is also useful for preventing type 2 diabetes.

Caution should be held as this study was conducted by the pharmaceutical company themselves and has not been published yet – so it is not yet peer-reviewed. However, if all goes well, the drug may become available on the market in a few year’s time.

Related article:

Poor sleep may undermine people’s attempts to keep weight off

Review highlights wealth of information on childhood obesity produced by groundbreaking Danish study

PrevPreviousThe Precise Neurons That Die In Parkinson’s Disease Have Finally Been Identified
NextNew insights on the importance of skull channels for brain healthNext

LATEST Blogs

Breakfast and health problems

Skipping Breakfast May Increase a Child’s Risk of Psychosocial Health Problems

September 7, 2022
James webb telescope

NASA’s Webb Space Telescope Captures a Cosmic Tarantula

September 7, 2022

Worse Than Smoking – Bad Sleep Can Worsen Lung Disease

August 31, 2022
Nanotechnology

Dr. Muhammad Adeel Addressed the International Con-ference as keynote speaker

August 23, 2022
Benefits of Mushrooms

Top 10 Health Benefits of Mushrooms, the Ultimate Superfood

August 18, 2022

New Way Invented To Produce Oxygen on Mars for Future Explorers

August 18, 2022

Evidence of Unprecedented Modern Sea-Level Rise Found in Ancient Caves

August 18, 2022

Research Shows Salt Substitutes Lower Risk of Heart Attack/Stroke and Death

August 13, 2022
covid symptoms

Hair Loss and Sexual Dysfunction Join Fatigue and Brain Fog in List of Long COVID Symptoms

August 13, 2022
protein

Most People Are Eating Too Much Protein – And It Has Serious Consequences

August 13, 2022

Categories

  • Scientific Blogs
  • Infinity Explorer
  • Traveler Book
  • Life Around

If you have tried to make a difference and you believe you deserve to be acknowledge, then please submit your story to us

Subscribe

Virtual Green Innovation Hub (VGI-H) is an emerging platform for young researchers which works as a bridge between You and the society.

Useful Links

Home
About us
Blogs

Subscribe Now

Don’t miss our future updates! Get Subscribed Today!

Copyright ©2022 Virtual Green Innovation Hub. All Rights Reserved.

Don’t miss our future updates. Get Subscribed Today!